Ogata Hiroaki, Koiwa Fumihiko, Kinugasa Eriko, Akizawa Tadao
Department of Internal Medicine, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-Chuo, Tsuzuki, Yokohama, 224-8503, Japan.
Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.
Clin Exp Nephrol. 2007 Dec;11(4):261-268. doi: 10.1007/s10157-007-0492-5. Epub 2007 Dec 21.
Chronic kidney disease (CKD) causes various bone mineral disorders, which have recently been named CKD mineral and bone disorder (CKD-MBD). CKD-MBD is associated with extremely high cardiovascular disease (CVD) morbidity and mortality in the endstage kidney disease (ESKD) population. Thus, optimal management of CKD-MBD would lead to a reduction in cardiovascular morbidity and mortality in uremic patients. In addition, it has been suggested that the treatment of CKD-MBD has some favorable effects on the progression of CKD. Recently, novel therapeutic agents, including active vitamin D analogues, noncalcium-containing phosphate binders, and cinacalcet, have become clinically available. In this article, we review novel therapeutic strategies for CKD-MBD.
慢性肾脏病（CKD）会引发各种骨矿物质紊乱，最近这些紊乱被命名为CKD矿物质与骨异常（CKD-MBD）。CKD-MBD与终末期肾病（ESKD）人群中极高的心血管疾病（CVD）发病率和死亡率相关。因此，对CKD-MBD进行优化管理将降低尿毒症患者的心血管发病率和死亡率。此外，有研究表明，CKD-MBD的治疗对CKD的进展具有一些有利影响。最近，包括活性维生素D类似物、不含钙的磷结合剂和西那卡塞在内的新型治疗药物已在临床上可用。在本文中，我们综述了CKD-MBD的新型治疗策略。
